Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 125
Filtrar
2.
J Emerg Med ; 55(4): 503-506, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-30037516

RESUMO

BACKGROUND: Computed tomography (CT) of the chest has replaced lung scans and pulmonary angiography as the criterion standard for the diagnosis of pulmonary embolism (PE). Most of these examinations are negative for PE, but they frequently have incidental findings that may require further evaluation. OBJECTIVE: In order to examine common incidental findings and their possible clinical ramifications and required workup, we reviewed data from relevant studies in which chest CTs were performed and incidental findings discovered. DISCUSSION: The most common incidental findings on chest CT are pulmonary nodules and lymph nodes. Nodules are significantly more commonly found in smokers and are also more likely to be malignant in smokers. The recently updated 2017 Fleischner Society recommendations provide guidance to clinicians in deciding which nodules should be further evaluated. Enlarged lymph nodes similarly represent potential malignancy and most will need further evaluation with positron emission tomography scans or by transbronchial needle aspiration. CONCLUSIONS: Enlarged lymph nodes and pulmonary nodules are both common incidental findings on chest CT. Each represents the potential for malignancy, and under certain conditions requires additional workup and further evaluation. The majority will be benign, even in high-risk populations. However, because of the increasing prevalence of the chest CT and the frequency with which incidental findings will be seen, it is important that the emergency physician be aware of common features and recommended subsequent evaluation.


Assuntos
Achados Incidentais , Pneumopatias/diagnóstico , Tórax/diagnóstico por imagem , Tomografia Computadorizada por Raios X/tendências , Humanos , Linfonodos/anormalidades , Linfonodos/fisiopatologia , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/diagnóstico por imagem , Tomografia Computadorizada por Raios X/métodos
4.
J Paediatr Child Health ; 53(11): 1091-1095, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29148187

RESUMO

Lateral neck lumps are very common in children, and are largely benign in nature. The majority of lumps may be diagnosed on history and clinical examination alone, and further investigations are often not required. The most common pathologies in young children include reactive lymphadenopathy, lymphadenitis and atypical mycobacterial infections. A lateral neck lump is an uncommon presentation for malignancy and is largely restricted to older children and adolescents. The paediatric surgeon plays an important role in the assessment and management of lateral neck lumps, often in the form of reassurance to the patients and their carers.


Assuntos
Linfonodos/anormalidades , Linfadenopatia/diagnóstico , Pescoço/patologia , Adolescente , Fatores Etários , Criança , Pré-Escolar , Diagnóstico Diferencial , Feminino , Humanos , Lactente , Linfadenopatia/etiologia , Masculino , Infecções por Micobactéria não Tuberculosa/diagnóstico
5.
Int J Pediatr Otorhinolaryngol ; 97: 72-75, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28483255

RESUMO

OBJECTIVES: To evaluate radiographic characteristics and to identify locations of cervicofacial lymphatic malformations in children based on known lymph node groupings. METHODS: Retrospective chart review of pediatric patients with cervicofacial lymphatic malformations who underwent imaging with magnetic resonance imaging (MRI), computed tomography (CT) or ultrasonography (US). Ninety charts were reviewed from November 2005 to June 2015. Demographic information and imaging characteristics were evaluated. RESULTS: Ninety children were included. The average age at presentation was 52 months (range, 1 day to 170 months). Imaging modalities were MRI in 73 (81%), CT in 7 (8%), US in 6 (7%), and multimodality imaging in 4 (4%) cases. Nearly half (49%) of lesions were found in the parotid and submandibular nodal group, 32% in the cervical group, and 19% in the midline face and oral cavity group. The lymphatic malformations were found on the left in 39 (43%) of cases, on the right in 30 (33%) of cases, and were bilateral in 21 (23%) cases. Nineteen (21%) lesions were macrocystic, twenty-two (24%) were microcystic, and forty-nine (49%) had mixed features. Mixed lesions were more likely to be extensive and involve multiple lymph node groups (P = 0.0005). Adjacent lymphadenopathy was present in 20 (22%) among all subjects, with an average size of 1.22 (± 1.92) cm in the short-axis. CONCLUSION: The results of this study demonstrate three lymph node groupings in which LM are commonly identified. The midline face and oral cavity lesions are predominantly microcystic, the parotid and submandibular lesions are predominately of mixed morphology, and the cervical lesions are predominately macrocystic and mixed. Further studies are needed to determine if such a classification system demonstrates clinically significant difference in disease progression and response to therapy.


Assuntos
Face/patologia , Linfonodos/anormalidades , Anormalidades Linfáticas/diagnóstico por imagem , Pescoço/patologia , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Imagem por Ressonância Magnética , Masculino , Estudos Retrospectivos , Tomografia Computadorizada por Raios X
6.
Rev. méd. Minas Gerais ; 27: [1-4], jan.-dez. 2017.
Artigo em Português | LILACS | ID: biblio-1006634

RESUMO

Trata-se de apresentação da Análise da Imagem de lesões cutâneas e intracranianas reveladas pelo exame clínico direto e radiológico, em que características clínico-epidemiológicas e de exames complementares permitem a identificação de agente etiológico mais provável, e revela gravidade extrema de nosologia eminentemente brasileira, que requer alerta para seu diagnóstico precoce e tratamento adequado para impedir sequelas e morte precoce. (AU)


This is a presentation of the Image Analysis of cutaneous and intracranial lesions revealed by direct clinical and radiological examination, in which clinical-epidemiological and complementary features allow the identification of the most probable etiological agent, and reveals extreme severity of nosology in Brazil, which requires alertness for its early diagnosis and appropriate treatment to prevent sequelae and early death. (Au)


Assuntos
Humanos , Masculino , Adulto , Paracoccidioidomicose , Paracoccidioidomicose/diagnóstico , Paracoccidioidomicose/tratamento farmacológico , Cérebro/lesões , Paracoccidioidomicose/diagnóstico por imagem , Gânglios da Base/lesões , Lesões dos Tecidos Moles , Extremidade Inferior , Linfonodos/anormalidades
7.
Zhonghua Zheng Xing Wai Ke Za Zhi ; 33(2): 84-90, 2017 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-30070800

RESUMO

Objective: To assess the therapeutic effect of management for lymphatic malformation (LM) in infants. Methods: This retrospective study recruited clinical data of 996 patients with LM from June 2004 to July 2015 in our center. All patients were diagnosed as LM after ultrasound, CT or MR scan. All patients were divided into Group 1 (427 patients, treated by endoscopic LM partial resection combined with cautery and postoperative intratumoral negative pressure and absolute ethyl alcohol),Group 2 (239 patients, treated by combined pinyangmycin and dexamethasone injection),Group 3 (330 patients, treated by surgical resection only).The clinical effects were observed in three groups, and therapeutic effect differences in gender, age, maximum diameter, location, range, histological typing, lymph property and treatments were analysed in cervicofacial LM. Results: Group 1:333 patients were cured (78.0%),Group 2:165 patients were cured (69.0%),Group 3:238 patients were cured (72.1%).The difference in cure rate between Group 1 and Group 2 or between Group 1 and Group 3 was significant(P <0.05).The number of patients with ≥ 2 treatments in Group 3 was significantly less than that in other two groups. The cure rate of LM in cervicofacial area was significantly lower than that in other parts of body (P < 0.05).In cervicofacial LM patients, the therapeutic effect differences in maximum diameter, range, histological typing, lymph property were statistically significant (P < 0.05).At the multivariable logistic regression analysis, LM range as well as histological typing were independent factors influencing the therapeutic effect (P < 0.05). Conclusions: Both treatment of endoscopic LM partial resection combined with cautery and postoperative intratumoral negative pressure and absolute ethyl alcohol, and surgical resection have good therapeutic effect on LM in infants. LM range as well as histological typing are important factors independently influencing the therapeutic effect of cervicofacial LM in infants.


Assuntos
Linfonodos/anormalidades , Antineoplásicos Hormonais/uso terapêutico , Cauterização/métodos , Terapia Combinada , Dexametasona/uso terapêutico , Medicamentos de Ervas Chinesas/uso terapêutico , Etanol/uso terapêutico , Feminino , Humanos , Lactente , Excisão de Linfonodo , Linfonodos/diagnóstico por imagem , Masculino , Estudos Retrospectivos
8.
Rev. senol. patol. mamar. (Ed. impr.) ; 29(1): 13-18, ene.-mar. 2016. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-149866

RESUMO

Objetivo. Comparar la supervivencia del cáncer de mama en mujeres que han sido cribadas en el programa de Detección Precoz del Cáncer de Mama (DPCM) y en las que no han participado en él. Pacientes y métodos. Es un estudio descriptivo y longitudinal en el que se han estudiado todos los cánceres de mama registrados en el servicio de Anatomía Patológica del Hospital de Tortosa Verge de la Cinta (Tarragona) de mujeres de 50-65 años, que se habían detectado la enfermedad ellas mismas o que la había detectado el programa DPCM, desde junio de 1999 hasta junio de 2003. Se registraron 101 pacientes con cáncer de mama, de las que en 84 se pudieron recoger todos los datos relativos al tumor, la cirugía y el tratamiento. En el 2014, tras un seguimiento de 11,6 ± 1,8 años, se anotó el estado actual. Resultados. No hay diferencia estadísticamente significativa en la supervivencia de los 2 grupos. Pacientes con carcinoma in situ y sin ganglios metastásicos se encuentran entre las fallecidas, mientras que ninguna paciente con carcinoma bien diferenciado falleció. Conclusiones. En nuestro estudio, el cribado del cáncer de mama no mejora la supervivencia y determinados factores en los que se apoyan los programas de cribado, como la detección de carcinomas no infiltrantes y/o de ganglios no metastásicos, no aseguran la curación (AU)


Objective. To compare survival in breast cancer between women diagnosed in an early breast cancer detection programme and those not attending this programme. Patients and methods. We conducted a descriptive and longitudinal study that analysed all types of breast cancer registered in the Pathology Service of the Hospital de Tortosa Verge de la Cinta (Tarragona, Spain). Tumour samples were obtained from 50-65-year-old women who had detected alterations on self-examination and from those attending the early breast cancer detection programme from June 1999 to June 2003. All the information relating to the tumour, surgery or treatment was registered. In 2014, after a follow-up of 11.6 ± 1.8 years, the current status of each patient was recorded. Results. There was no significant statistical difference in survival between the two groups of patients. Non-survivors included patients with in situ carcinoma and without lymph node metastases. Survival was 100% in patients with well differentiated carcinoma. Conclusions. Breast cancer screening did not improve survival in our study. The elements on which screening programs are based, such as non-invasive carcinoma detection and/or non- metastatic lymph nodes, do not ensure recovery (AU)


Assuntos
Humanos , Feminino , Adulto , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Programas de Rastreamento/classificação , Programas de Rastreamento/métodos , Linfonodos/metabolismo , Espanha/etnologia , Biópsia de Linfonodo Sentinela/métodos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/terapia , Intervalo Livre de Doença , Programas de Rastreamento/normas , Programas de Rastreamento , Linfonodos/anormalidades , Biópsia de Linfonodo Sentinela/normas
9.
Rev. senol. patol. mamar. (Ed. impr.) ; 29(1): 32-39, ene.-mar. 2016. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-149869

RESUMO

En 1992 el Colegio Americano de Radiología (ACR) publicó la primera edición del breast imaging reporting and data system (BI-RADS(R)), un sistema para clasificar los hallazgos mamográficos. Desde entonces se ha convertido en una herramienta fundamental en: la descripción de los hallazgos por imagen de la mama, la asignación en categorías diagnósticas estableciendo el grado de sospecha, la actitud a seguir en cada caso y la estandarización del informe radiológico. Los cambios principales de la 5.a edición del BI-RADS(R) tienen como objeto dar más flexibilidad en situaciones donde las ediciones pasadas creaban confusión. La nueva edición ha introducido cambios en el léxico radiológico, en la estandarización del informe, en la monitorización de los resultados y en el manejo del paciente en algunas situaciones clínicas. Para facilitar la comprensión del informe radiológico, algunos descriptores se han eliminado y otros se han modificado. También se han unificado los descriptores de determinados hallazgos en los distintos métodos de imagen (mamografía, ultrasonidos y resonancia magnética). En cuanto a la categoría BI-RADS(R), ahora los radiólogos pueden añadir información adicional y especificar si se debe hacer biopsia en lugar de seguimiento en base a circunstancias clínicas. En el atlas se incluye un mayor número de imágenes y citas bibliográficas (AU)


The breast imaging reporting and data system (BI-RADS(R)) was first published by the American College of Radiology in 1992, with the objective of classifying mammographic findings. Since then, it has become an essential tool for the description of imaging findings in breast lesions, the determination of diagnostic categories to establish the degree of suspicion, the approach to be taken, and the standardization of the radiology report. The main changes in the 5.th edition aim to provide greater flexibility in those situations that gave rise to confusion in the previous editions. The new edition has introduced changes in the radiological lexicon, report standardization, monitoring of the results and management of the patient in specific clinical situations. To simplify the report, some descriptors have been eliminated and others have been modified. Additionally, some descriptors have been unified among different imaging techniques (mammography, ultrasound and magnetic resonance). Concerning BI-RADS(R) category, radiologists can now add additional information to specify if a biopsy should be performed instead of clinical follow-up. More images and literature references have been included in the atlas (AU)


Assuntos
Humanos , Feminino , Adulto , Mamografia/instrumentação , Mamografia/métodos , Radiologia/métodos , Calcificação Fisiológica/genética , Dermatopatias/genética , Dermatopatias/metabolismo , Linfonodos/anormalidades , Cisto Mamário/genética , Mamografia/normas , Mamografia , Radiologia/classificação , Calcificação Fisiológica/fisiologia , Dermatopatias/complicações , Dermatopatias/diagnóstico , Linfonodos/metabolismo , Cisto Mamário/cirurgia
10.
Clin. transl. oncol. (Print) ; 18(3): 251-258, mar. 2016. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-148708

RESUMO

Tumor-associated macrophages (TAMs) are major component of leukocytic infiltrate of tumors and play important roles in progression and regression of tumors. Tumor microenvironment determines the mutual conversion between M1 and M2 macrophages. In many kinds of tumors, M2 type macrophages are of the majority in TAMs and promote tumor progression and metastasis. The dynamic balance and interaction between TAMs and tumor cells have important effects on the occurrence and development of tumor. TAMs in malignant tumors are useful for clinical diagnosis and may provide a novel target for cancer treatment (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Macrófagos/citologia , Fatores de Necrose Tumoral/farmacologia , Leucócitos/citologia , Lipopolissacarídeos/química , Proteínas Proto-Oncogênicas c-sis/administração & dosagem , Linfonodos/metabolismo , Análise do Polimorfismo de Comprimento de Fragmentos Amplificados/métodos , Carcinoma Hepatocelular/patologia , Neoplasias Gástricas/tratamento farmacológico , Helicobacter pylori/citologia , Macrófagos/classificação , Fatores de Necrose Tumoral/metabolismo , Leucócitos/química , Lipopolissacarídeos , Proteínas Proto-Oncogênicas c-sis/classificação , Linfonodos/anormalidades , Análise do Polimorfismo de Comprimento de Fragmentos Amplificados , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Gástricas/radioterapia , Helicobacter pylori/metabolismo
11.
Clin. transl. oncol. (Print) ; 18(3): 296-303, mar. 2016. tab, ilus, graf
Artigo em Inglês | IBECS | ID: ibc-148714

RESUMO

Objective This study was conducted to explore the prognostic value of the methylation status of the ASC/ TMS1 (apoptosis-associated speck-like protein containing a CARD/the target of methylation-induced silencing-1) promoter in gastric cancer (GC). Methods ASC/TMS1 expression was detected in GC tissues and normal gastric mucosal tissues by real-time quantitative PCR and Western blot analysis. Methylationspecific PCR (MSP) analysis was performed to detect the methylated degrees of the DNA of the ASC/TMS1 promoter of 200 GC patients. Associations between molecular, clinicopathological characteristics and survival data were analyzed. Results The mRNA and protein expression levels of ASC/TMS1 in GC tissues were lower than those in normal gastric mucosal tissues. With the MSP detection, ASC/ TMS1 promoter methylation was found in 68 (34 %) in 200 GC tissues, while none of 40 normal gastric mucosal tissues were found to be methylated. The size of primary tumor and lymph node metastasis were identified as independent relative factors of methylation status of the ASC/ TMS1 promoter in GC tissues. Multivariate analysis results demonstrated that the degree of differentiation, serosal invasion, lymph node metastasis and methylated status of ASC/TMS1 promoter were independent prognostic indicators of GC. Lymph node metastasis and methylated status of ASC/TMS1 promoter were optimal prognostic predictors of GC patients, as identified by Cox regression with Akaike information criterion value calculation. Conclusions The methylated status of ASC/TMS1 promoter had the potential applicability for clinical evaluation the prognosis of GC (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Neoplasias Gástricas/patologia , Carcinógenos/administração & dosagem , Apoptose/genética , Linfonodos/metabolismo , Metilação , Preparações Farmacêuticas/administração & dosagem , Assistência Ambulatorial/métodos , Tomografia Computadorizada por Raios X/métodos , Neoplasias Pulmonares/patologia , Neoplasias da Mama/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Carcinógenos/metabolismo , Apoptose/fisiologia , Linfonodos/anormalidades , Preparações Farmacêuticas/metabolismo , Assistência Ambulatorial/normas , Tomografia Computadorizada por Raios X/instrumentação , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias da Mama/complicações
12.
Clin. transl. oncol. (Print) ; 18(3): 317-321, mar. 2016. tab
Artigo em Inglês | IBECS | ID: ibc-148716

RESUMO

Purpose To analyze clinical-dosimetric predictors of genitourinary (GU) toxicity in a cohort of prostate cancer (PC) patients treated with moderate hypofractionation and simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT) technique. Materials and methods 60 patients were selected. Patients were stratified into low (43 %), intermediate (30 %) and high-risk (27 %) groups. Low-risk patients received 73.5 Gy to PTV1; intermediate-risk received 73.5 Gy to PTV1 and 60 Gy to PTV2; high-risk received 73.5 Gy to PTV1, 60 Gy to PTV2, and 54 Gy to PTV3. All patients were treated in 30 fractions. Androgen deprivation therapy (ADT) was prescribed upfront in intermediate and high-risk categories. Toxicity was scored according to Common Terminology Criteria for Adverse Events v4.0 scoring system. Results Median follow-up was 30 months (range 16–36 months). GU acute toxicity was recorded as followS: G0 = 16/60 (27 %), G1 = 18/60 (30 %); G2 = 26/ 60 (43 %). GU late toxicity was recorded as follows: G0 = 20/60 (34 %); G1 = 29/60 (48 %); G2 = 11/56 (18 %). The risk of acute G2 GU toxicity was three times higher for prostate volume C80 cc. In 60 % of the patients with a prostate volume C80 cc, the first 3 weeks are at particular risk for toxicity onset. In the late setting, no statistical significance was found between GU toxicity and prostate gland dimension. Conclusion Prostate volume C80 cc resulted a predictive factor of acute G2 GU toxicity, in moderate hypofractionation and volumetric modulated arc radiation therapy for definitive PC (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Neoplasias da Próstata/patologia , Terapêutica/métodos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/metabolismo , Anormalidades Urogenitais/genética , Tomografia Computadorizada por Raios X/métodos , Linfonodos/patologia , Retenção Urinária/patologia , Espectroscopia de Ressonância Magnética , Estudos Retrospectivos , Neoplasias da Próstata/tratamento farmacológico , Terapêutica/instrumentação , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/complicações , Anormalidades Urogenitais/patologia , Estudos Prospectivos , Tomografia Computadorizada por Raios X/instrumentação , Linfonodos/anormalidades , Retenção Urinária/diagnóstico , Espectroscopia de Ressonância Magnética/métodos
13.
Clin. transl. oncol. (Print) ; 18(3): 283-288, mar. 2016. tab, graf
Artigo em Inglês | IBECS | ID: ibc-148965

RESUMO

Objectives MicroRNA-200 family (miR-200f) has been consistently reported to be deregulated and modulate the metastatic process in multiple cancers. In the present study, we detected the expression of miR-200f in breast cancer (BC) tissue and explored its relationships with clinicopathological characteristics, especially with lymph node metastasis. Methods Expression levels of miR-200a, miR-200b, miR-200c, miR-141, and miR-429 in 99 pairs of BC tissues and adjacent normal tissues were measured by real-time quantitative PCR. The correlation between miR-200f level and multiple clinicopathological factors was then examined by Mannû Whitney test, ANOVA, and operating characteristic (ROC) analysis. Results All members of the miR-200f were down-regulated in BC tissue compared with that in normal adjacent tissue; miR-200a, miR-200b, and miR-200c were highly decreased (p\0.05), while the differences of miR-141 and miR-429 between patients and the control group were not statistically significant. Furthermore, all five members were found to be distinctly decreased with the incidence of lymph node metastasis (p\0.05); When the patients were divided into three groups according to the number of lymph node metastasis (0; 1û3; C4), a gradual decrease of miR-200f expression was observed with the increasing number of lymph node metastasis; ROC revealed that miR-200b can differentiate patients with lymph node metastasis from those without lymph node metastasis. Conclusion These observations imply that the down regulation of miR-200f in human BC is associated with an invasive phenotype, and miR-200b may be useful to estimate the likelihood of the presence of pathologically positive lymph nodes (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Linfonodos/metabolismo , Tórax/metabolismo , MicroRNAs/genética , Neoplasias da Mama/patologia , Psicopatologia/educação , Carcinoma Ductal/tratamento farmacológico , Metástase Linfática/genética , Preparações Farmacêuticas/administração & dosagem , Terapêutica/métodos , Terapêutica , Terapêutica/instrumentação , Terapêutica/normas , MicroRNAs/administração & dosagem , Linfonodos/anormalidades , Tórax/anormalidades , Neoplasias da Mama/tratamento farmacológico , Psicopatologia/ética , Carcinoma Ductal/radioterapia , Metástase Linfática/patologia , Preparações Farmacêuticas/metabolismo
15.
Clin. transl. oncol. (Print) ; 18(2): 220-227, feb. 2016. tab, graf, ilus
Artigo em Inglês | IBECS | ID: ibc-148228

RESUMO

Objective. To examine the expression of cortactin in epithelial ovarian cancer, and discuss the relationship between the expression of cortactin and the clinical pathology characteristics in epithelial ovarian cancer, as well as clinical significance. Methods. The expression of cortactin was detected using real-time fluorescence quantitative PCR and immunohistochemical SP method in epithelial ovarian cancer. Results. (1) The relative content of cortactin mRNA in epithelial ovarian cancer tissue was higher than that in benign control tissue, and expression was related to histological classification and FIGO stage. (2) Cortactin protein was localized in the cytoplasm and membrane of tumor cells. The positive rate of cortactin was 73.3 % in epithelial ovarian cancer, and the rate of cortactin expression was related to histological classification. (3) The average survival period of epithelial ovarian cancer patients with positive expression of cortactin was 19.5 ± 1.2 months (95 % CI 14.6–21.4 months), compared with 34.5 ± 4.3 months in the negative expression group (95 % CI 22.1–25.9 months). Univariate survival analysis showed that: negative expression of cortactin had a significant survival advantage (χ 2 = 5.739, P = 0.017). A cox regression model for multivariate analysis revealed that cortactin was an independent prognostic factor for epithelial ovarian cancer (P = 0.001; RR = 6.452, 95 % CI 2.289–7.112). Conclusions. Negative expression of cortactin was an independent prognostic factor and had a survival advantage. This suggested that cells with poor differentiation showed increasing motility. Cortactin is closely related to poor prognosis (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Cortactina/administração & dosagem , Cortactina/metabolismo , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/mortalidade , Linfonodos/anormalidades , Linfonodos/metabolismo , Ascite/metabolismo , Hepatite A/patologia , Neoplasias Pancreáticas/patologia , Cortactina , Cortactina/farmacologia , Neoplasias Ovarianas/complicações , Neoplasias Ovarianas/metabolismo , Linfonodos/fisiologia , Ascite/complicações , Hepatite A/complicações , Intervalo Livre de Doença , Neoplasias Pancreáticas/complicações
16.
Clin. transl. oncol. (Print) ; 18(1): 18-26, ene. 2016. ilus, graf
Artigo em Inglês | IBECS | ID: ibc-148047

RESUMO

Background. To determine the effects of endostatin on vascular growth factor receptor 2 (VEGFR2) expression in non-small cell lung cancer (NSCLC) cells and the mechanisms underlying its radiosensitizing effect. Methods. VEGFR2 mRNA levels were determined in different NSCLC cell lines using qRT-PCR. RT-PCR and Western blot assays were used to assess the expression of mRNA and proteins. The radiosensitivity of the cells was determined by colony-formation assays; and cell apoptosis and cell cycle distribution were determined by flow cytometry. Results. VEGFR2 mRNA levels differed among the five NSCLC cell lines (P < 0.01), with the highest expression in Calu-1 cells and lowest in A549 cells. Endostatin significantly inhibited the growth of Calu-1 cells (P < 0.01) (IC20 = 296.5 μg/ml), and the expression of VEGFR2 and HIF-1α (P < 0.05). Phosphorylation of protein kinase B (Akt), extracellular signal-regulated kinases 1/2 (ERK1/2), and p38 were significantly lower in endostatin-treated cells than control (P < 0.05). Endostatin enhanced the radiosensitivity of Calu-1 cells to SER = 1.38 and induced apoptosis (P < 0.01) and G2/M blockage (P < 0.01). However, endostatin had limited effects on A549 cells. Compared with Calu-1 cells, there was not significantly effects on cell radiosensitivity (SER = 1.09). Conclusions. Endostatin induces apoptosis and enhances radiosensitivity of the VEGFR2 high-expressing cell line Calu-1, but it has a limited effect on the VEGFR2 low-expressing cell line A549 (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Endostatinas/administração & dosagem , Endostatinas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/patologia , Apoptose/genética , Citometria por Imagem/métodos , Linfonodos/metabolismo , Células Gigantes/citologia , Endostatinas , Endostatinas/provisão & distribução , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/radioterapia , Apoptose/fisiologia , Citometria por Imagem/instrumentação , Linfonodos/anormalidades , Células Gigantes/metabolismo , China/etnologia
17.
Clin. transl. oncol. (Print) ; 18(1): 58-64, ene. 2016. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-148052

RESUMO

Background. To test the feasibility of radiotherapy dose escalation using volumetric arc therapy (VMAT) and image-guided radiotherapy (IGRT) with concurrent chemotherapy in locally advanced cervix cancer (LACC) and compare this with whole-pelvis three-dimensional conformal radiation therapy (CRT) in terms of clinical toxicity. Methods. Database was reviewed for all LACC patients treated during 2011 and 2012. Twenty patients who were treated with escalated dose of radiotherapy using VMAT were selected for analysis. A matched cohort of 40 patients who had 3DCRT between 2005 and 2008 was selected as control. Mean basal hemoglobin, average weekly hemoglobin, and maximal drop in hemoglobin were measured for both 3DCRT and VMAT groups and treatment toxicity scored according to RTOG criteria. Charts were also reviewed for other acute and late toxicities including the rate of compliance with prescribed treatment. Results. Mean age was 46 (30–63) and 47 years (33–67), mean tumor size was 5.5 and 5 cm and blood transfusion rate was 55 and 45 % in CRT and VMAT groups, respectively. Hemoglobin toxicity (Grade I–II) was encountered in 97.5 and 90 % (p 0.0.3) while Grade I–III Leukopenia was 90 and 70 % (p 0.02), respectively. There was no Grade 3 or 4 GI or GU toxicity. Conclusion. VMAT/IGRT with dose escalation is feasible in LACC without excessive toxicity as compared to CRT “Box”. We propose a randomized control trial of this novel approach of higher radiation dose and volume against the standard prescription based on CRT (AU)


No disponible


Assuntos
Humanos , Feminino , Adulto , Neoplasias do Colo do Útero/metabolismo , Neoplasias do Colo do Útero/patologia , Quimioterapia Adjuvante/métodos , Quimioterapia Adjuvante/normas , Dosagem/prevenção & controle , Radioterapia Adjuvante/métodos , Radioterapia Adjuvante/psicologia , Linfonodos/metabolismo , Controle da Radiação/métodos , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/terapia , Quimioterapia Adjuvante/classificação , Quimioterapia Adjuvante/enfermagem , Dosagem/classificação , Radioterapia Adjuvante/classificação , Radioterapia Adjuvante/normas , Linfonodos/anormalidades , Controle da Radiação/análise
18.
Vet Radiol Ultrasound ; 57(1): 65-74, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26456541

RESUMO

Ultrasonography and radiography are commonly used for staging of lymphoma in horses, however there is little published information on imaging characteristics for horses with confirmed disease. The purpose of this retrospective, case series study was to describe ultrasonographic and radiographic findings for a group of horses with a confirmed diagnosis of lymphoma. A total of 13 horses were sampled. Lymphadenopathy (8/13), peritoneal effusion (6/13), splenic (6/13), and hepatic (5/13) lesions were the most frequently identified. The predominant splenic and hepatic ultrasonographic lesions were hypoechoic nodules, organomegaly, and changes in echogenicity. Digestive tract lesions were detected in three horses and these included focal thickening and decreased echogenicity of the small (2/13) and large intestinal (2/13) wall. Thoracic lesions were predominantly pleural effusion (4/13), lymphadenopathy (4/13), and lung parenchymal changes (3/13). Enlarged lymph nodes were detected radiographically (4/13) and/or ultrasonographically (2/13) in the thorax and ultrasonographically in the abdomen (7/13) and in the caudal cervical region (4/13). Findings supported the use of abdominal and thoracic ultrasonography for lymphoma staging in horses. Ultrasound landmarks for localizing cecal and caudal deep cervical lymph nodes were also provided.


Assuntos
Líquido Ascítico/diagnóstico por imagem , Doenças dos Cavalos/diagnóstico por imagem , Fígado/diagnóstico por imagem , Linfonodos/diagnóstico por imagem , Linfadenopatia/veterinária , Linfoma/veterinária , Baço/diagnóstico por imagem , Animais , Bélgica , Feminino , Cavalos , Fígado/patologia , Linfonodos/anormalidades , Linfadenopatia/diagnóstico por imagem , Linfoma/diagnóstico por imagem , Masculino , Radiografia/veterinária , Estudos Retrospectivos , Baço/patologia , Ultrassonografia/veterinária
19.
Med Care Res Rev ; 73(5): 546-64, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-26613702

RESUMO

We studied differences in access to large or accredited cancer programs as a possible explanation for geographic disparities in adherence to the national guideline on lymph node assessment for Stages I to III colon cancer. State cancer registries were linked with Medicare claims of patients diagnosed from 2006 to 2008 from Appalachian counties of four states. Metropolitan and nonmetropolitan patients differed on adherence, proximity to high-volume or accredited hospitals, and hospital type. We modeled effects of hospital type on adherence with ordinary least squares and instrumental variables (instrumenting for hospital type with relative distance). The evidence was strongest for improved adherence in high-volume hospitals for nonmetropolitan patients. We estimate that roughly 100 deaths might be prevented over 5 years among each year's incident cases if the nonmetropolitan disparity in hospital volume were eliminated nationally. We conclude that regionalization or targeting smaller hospitals would improve adherence in nonmetropolitan areas, but also argue for improving adherence generally.


Assuntos
Neoplasias do Colo/epidemiologia , Fidelidade a Diretrizes/normas , Hospitais/normas , Linfonodos/anormalidades , Idoso , Idoso de 80 Anos ou mais , Região dos Apalaches/epidemiologia , Neoplasias do Colo/mortalidade , Feminino , Hospitais/estatística & dados numéricos , Humanos , Masculino , Medicare , População Rural , Estados Unidos , População Urbana
20.
Cir Pediatr ; 29(2): 77-81, 2016 Apr 10.
Artigo em Espanhol | MEDLINE | ID: mdl-28139107

RESUMO

OBJECTIVES: To analyze and describe the association between the development of venous aneurysms of the mayor vessels in patients with lymphatic malformations. MATERIAL AND METHODS: Retrospective review of patients diagnosed with both VA and LM from 1993 to 2014 and a descriptive analysis of clinical course was performed. RESULTS: We found 6 patients, 50% females, who had LM and VA confirmed with imaging techniques. All were diagnosed between 20 weeks- 12 years of age. LM were found within the thoracic cavity (n= 4), intrathoracical-cervical area (n= 1) and lower extremities (n= 1). In most cases the dilated veins were near the LM and thus, the mediastinal vessels were most commonly affected (superior vena cava-innominated (n= 1), venous jugulosubclavian confluence (n= 2), superior vena cava (n= 2) and popliteal vein (n= 1)). A total of 4 patients required surgical treatment of the LM with complete excision in 2 of the cases. Patients with a prenatal diagnosis of lymphatic malformation were most likely to present venous aneurysms at birth (n= 2), however the remaining patients (without prenatal diagnosis) developed them later on (average 6 years). Unlike lower extremity aneurysms, none of these aneurysms grew or required antiplatelet therapy; local thrombosis developed in one which resulted in pulmonary thromboembolism and one developed mitral valve insufficiency (regurgitation?) which required valve replacement. CONCLUSION: VA is extremely rare, and there is not therapeutic algorithm, therefore treatment should be individualized.


Assuntos
Aneurisma/diagnóstico por imagem , Linfonodos/anormalidades , Veias/diagnóstico por imagem , Aneurisma/terapia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Medicina de Precisão , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA